The Changing Therapeutic Landscape in Metastatic Prostate Cancer in the CHAARTED trial. About 77% of patients in this cohort were able to complete all six planned cycles of docetaxel. The median OS benefit with the addition of docetaxel was approximately 10 months compared with ADT alone (81 versus 71 months). Patients who received chemotherapy had a 22% reduction in risk of all-cause death (HR 0.78). Pre-determined intermediate outcomes including prostate cancer specific survival benefit and failure-free survival (FFS) also favored the addition of docetaxel. The M0 patient cohort had smaller numbers of enrolled patients with fewer deaths at last interim analysis and with an insufficient number of events to determine a potential benefit for docetaxel in this setting. Several other clinical trials have addressed the benefit of adding docetaxel to ADT for patients with hormone-sensitive high-risk non-metastatic or metastatic prostate cancer. [7] [8] [9] Benefits have been seen for FFS but with contrasting results with regard to OS.
Early use of abiraterone in metastatic hormonesensitive prostate cancer-results from the LATTITUDE and STAMPEDE trials
Abiraterone acetate (Zytiga ® ; Janssen, Beerse, Belgium) blocks the production of testicular, adrenal, and intra-tumor tissue/cell androgens resulting in a decrease in downstream androgen receptor (AR) signaling.
Since AR signaling is necessary for androgen sensitive cell proliferation, 10 it was postulated that abiraterone would have activity in earlier stages of the disease. A phase II trial of neoadjuvant abiraterone in combination with leuprolide and prednisone prior to radical prostatectomy, showed a pathologic complete response (CR), or near CR, in one-third of men with high-risk, localized prostate cancer. 11 The results of two studies confirmed that early use of abiraterone significantly improves survival in men with metastatic hormone-sensitive prostate cancer. In the LATTITUDE phase III trial, 1,199 men with mHSPC were randomized to receive either ADT therapy plus abiraterone acetate (1,000 mg daily) plus prednisone (5 mg daily), or ADT plus dual placebo. 12 Patients enrolled had at least two of the following three risk factors:
Gleason score 8 or higher, three or more bone lesions, or measurable visceral metastases. The co-primary end points were OS and radiographic progression-free survival (rPFS). At the first interim analysis, after a median follow-up of 30.4 months, the median survival had not been reached in the abiraterone-treated group; the median OS in the control group was 34.7 months (HR 0.62; p<0.001). The 3 year OS for patients treated with abiraterone was 66% versus 49% in the placebo arm. The median duration of rPFS was 33.0 months in the abiraterone arm versus 14.8 months in the placebo arm (HR for disease progression = 0.47; p<0.001). Patients receiving abiraterone had higher rates of grade 3/4 adverse events (AEs) compared with the control arm. These included hypertension (20.3% versus 10.0%), hypokalemia (10.4% versus 1.3%), and elevated liver transaminases, alanine aminotransferase (ALT; 5.5% versus 1.3%), and aspartate aminotransferase (AST; 4.4% versus 1.5%). 12 In the STAMPEDE trial, 1,917 patients with newly diagnosed locally advanced or high-risk mHSPC were randomized 1:1 to receive either abiraterone acetate (1,000 mg daily) plus prednisone (5 mg daily), plus standard of care (SOC) or SOC alone, defined as the administration of ADT therapy for 2 years or until disease progression. 13 At time of study entry, 95% of patients were newly diagnosed, 52% had metastatic disease, and 88% had disease that had metastasized to bone. At a median follow-up of 40 months, 184 deaths had occurred in the abiraterone arm and 262 deaths in the SOC arm. 14 Patients receiving sipuleucel-T had an improvement in OS of 4.1 months compared with the placebo arm and a 22% reduction in the risk of death. The survival benefit was maintained in pre-specified subgroups that included Eastern Cooperative Oncology Group (ECOG) performance status (0 versus 1), Gleason score (<7 or >8), PSA level above or below median, and number of bone metastases (0-5, 6-10, >10). Currently there are no surrogate biomarkers for response to this vaccine or endpoints for survival. The optimal selection of patients who benefit the most from sipuleucel-T in IMPACT has been retrospectively reviewed by Schellhammer, et al. 15 The most important prognostic factor was baseline PSA. PSA levels were divided into quartiles to assess the predictive value at each quartile on OS. While all PSA quartile groups benefitted from sipuleucel-T, patients in the lowest baseline quartile (PSA <22) had the most benefit with an estimated improvement in medial survival of 13 months compared with 2.8 months in the highest quartile group (PSA >134). This supports the earlier use of sipuleucel-T in patients with metastatic disease. 
Viral-vector-based vaccines-PROSTVAC-VF
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The primary endpoint of this study was PFS. Although this end point was not met, OS after 3 years of follow-up was increased significantly in the PROSTAC-VF treated arm by 8.5 months (25.1 versus 16.6 months: HR 0.56; p=0.0061). In a subsequent phase II study, PROSTVAC-VF increased PFS by more than 6 months in 63% of patients. 17 There was also a significant slowing of the PSA doubling time from 5.3 months to 7.7 months. The PROSPECT Global phase III trial (NCT01322490) randomized men with non-symptomatic or minimally symptomatic mCRPC to one of three arms:
PROSTVAC-VF + adjuvant granulocyte-macrophage colony stimulating factor (GM-CSF) (arm 1); PROSTVAC-VF + adjuvant placebo (arm 2), or vector placebo (adjuvant placebo) (arm 3). No cross over was allowed and patients went on to receive SOC treatment following progression. PROSPECT has completed accrual and results from this trial are expected shortly.
Immune checkpoint inhibition in metastatic castration-resistant prostate cancer
Prostate cancers have a low mutation rate and limited CD8-T cell infiltration and rarely express programmed death 1 (PD-1), unlike bladder and renal cell cancers where PD-1/programmed death-ligand 1 (PD-L1) therapy is effective. 18 A phase Ib trial of nivolumab in 17 patients with advanced prostate cancer failed to show any objective responses. 19 Bishop et al. have demonstrated that non AR-mediated upregulation of PD-L1 expression occurs in both enzalutamide-resistant pre-clinical models and patients with prostate cancer. 20 In a recent phase II trial, patients who had progressed on enzalutamide were treated with the anti-PD-1 antibody pembrolizumab. 21 Three of the first 10 patients treated had rapid and significant decreases in PSA from pre-treatment levels of 46, 71, and 2,503 to <0.1. Two of the three patients with measurable disease (one with liver metastases) had a partial response and two were able to discontinue opiate analgesics. All three patients remain free of progression at 30, 55, and 16 weeks of followup. Two of the three responders had a baseline biopsy prior to starting pembrolizumab. Biopsies from these patients showed presence of CD8 tumor infiltration and PD-L1 expression. Of the remaining seven patients, three had stable disease at 30, 47, and 50 weeks, which were ongoing, and four patients had disease progression. Expected immune-related AEs were observed. None of the responders had an immune-related AE. 21 A phase III trial in men with locally advanced or mCRPC, comparing the anti-PD-L1 antibody, atezolizumab plus enzalutamide with enzalutamide alone, is currently in progress (NCT03016312).
Combination immunotherapy strategies
Despite the lack of efficacy of anti-PD-1/PD-L1 antibody monotherapy in the treatment of mCRPC, there is a renewed interest in exploring combination checkpoint inhibitors which can work synergistically to restore cellularmediated antitumor immunity. The cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and PD-1 pathways that inhibit both T-cell activation and T-cell function, have been the most well-defined and therapeutically active targets for checkpoint blockade. 22 Ipilimumab is an immuno-stimulatory antibody that inhibits CTLA-4 activity thereby enhancing the immune system's T cell's response to cancer. In a phase III randomized clinical trial, patients with mCRPC who had progressed on docetaxel were treated with a single dose of bone-targeted radiotherapy, and then randomized to Ipilimumab at a dose of 10 mg/kg or placebo, every 3 weeks for up to four cycles. 23 Although the primary endpoint of OS was not met, patients treated with Ipilimumab had an improvement in PFS of 4 months, compared with 3.1 months in the placebo arm (HR 0.70; p<0.001), and an improved PSA response (13.1% versus 5.2%). Data from a pre-specified and post-hoc subgroup suggested an OS benefit for ipilimumab in the subset of patients with better prognostic factors that included absence of visceral metastases, hemoglobin>10, and alkaline phosphatase <1.5 upper limit of normal (ULN).
The median OS in this subset of patients was 22.7 months with ipilimumab versus 15.8 months with placebo (HR 0.62; p=0.0038).
The combination of ipilimumab and nivolimab has shown significant improvement in median PFS in patients with metastatic melanoma compared with ipilimumab monotherapy. 24 In prostate cancer, Gao et al. have shown that while ipilimumab increased levels of tumor infiltrating T cells, it also increased levels of other compensatory inhibitory immune checkpoint molecules including PD-L1 and VISTA in tumor specimens from untreated and treated ipilimumab patients in a pre-surgical clinical trial. 25 These observations provide a rationale for combining ipilimumab and nivolumab in patients with prostate cancer, with the goal of targeting 
Androgen receptor signaling and the PI3k pathway and PTEN loss in prostate cancer
AR signaling occurs throughout the course of prostate cancer and drives cell growth and survival in early and late stages of the disease. Despite initial responses to ADT, resistance to treatment inevitably occurs due to AR reactivation and signaling, despite castrate levels of testosterone. AR gene amplification and overexpression, increased sensitivity to agonists, and ligand-independent AR reactivation mediated by AR splice variants also takes place, resulting in constitutive AR activation. Phosphoinositide 3-kinases (PI3ks) are lipid kinases that normally regulate basic cellular anabolic and catabolic processes, including protein synthesis, metabolism, proliferation, and survival. 27 In prostate cancer, however, the PI3k pathway is significantly de-regulated. 28 Aberrant PI3k/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling is present in 70-100% of men with advanced prostate cancer, 29 and loss of phosphatase and tensin homolog (PTEN) leads to activation of the phosphoketolase (PKT) pathway in approximately 60% of CRPC patients. 30 PTEN pathway activation is associated with resistance to ADT, disease progression, and poor outcomes in men with prostate cancer. 31 The development and clinical utility of agents that block the interaction between 
Treatment of patients with DNA repair alterations-the TOPARP-A trial
Genomic alterations that inactivate genes involved in the repair of DNA damage through homologous recombination (PARP), are present in approximately 22.7% of men with prostate cancer. 33 Men with metastatic prostate cancer and gene mutations such as PARP have sustained responses to PARP inhibitors and platinum-based chemotherapy (Figure 1 ).
In the pivotal TOPARP-A trial, 50 men with previously-treated mCRPC, received the oral PARP inhibitor, olaparib, at a dose of 400 mg twice daily until radiographic progression, clinical progression, or development of serious AEs. 34 The primary endpoint was overall response rate (ORR) defined as either objective response, PSA decrease of >50%, or reduction in the number of circulating tumor cells. Tumor biopsies from all patients were submitted for NGS, exome transcriptome analysis, and digital polymerase chain reaction testing. Several actionable mutations that relate to DNA repair pathways were identified including BRCA1, BRCA2, ATM, CHEK2, and FANCONI anemia genes (FANCA). One or more of these mutations was present in 16 patients (33%). BRCA2 mutations were present in seven patients (four with bi-allelic somatic loss, three with germline mutations), ATM mutations in five patients, homozygous somatic deletions of BRCA1 or CHEK2 with FANCA deletion in three patients, a somatic frameshift mutation in PALB2 (a localizer of BRCA2) in one patient with a heterozygous PALB2 deletion, and a bi-allelic somatic mutation in HDAC (which plays a role in ATM function) in one patient. Responses were seen in 14 of 16 patients (88%) with DNA-repair gene mutations, compared with two of 33 patients (6%) without these mutations (p<0.001).
Median rPFS was longer in mutation-positive patients with DNA-repair defects treated with olaparib than in the mutation-negative group (9.8 versus 2.7 months; p<0.001) as was OS (13.8 versus 7.5 months (p<0.05).
The most common grade >3 AEs were anemia (20%), fatigue (12%), and leukopenia (6%). Dose reduction of olaparib to 300 mg twice daily was required in 26% of patients, most commonly due to anemia. AEs led to treatment discontinuation in 6% of patients. 34 Based on these clinically significant results, olaparib received breakthrough designation by the US 
Summary
Prostate cancer is the most common cancer afflicting men in North America and is estimated to become the third leading cause of death behind lung cancer and colorectal cancers. 35 Although prostate cancers are clinically heterogeneous, AR signaling occurs in all stages of the disease and suppression of the AR remains the cornerstone of therapy.
The early addition of chemotherapy (docetaxel) or hormone therapy (abiraterone) to standard ADT for patients with newly diagnosed hormonesensitive metastatic disease, has resulted in a robust improvement in OS. 
